Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKlaudia ZielonkaBIBłażej IzdebskiJDJoanna Drozd‐Sokołowska

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports a 97.4% overall response in CLL patients with comorbidities, suggesting Ven-Obi is effective.

Key Points

  • The overall response rate for patients receiving Ven-Obi was 97.4%, highlighting its effectiveness as a treatment.
  • Complete remission was achieved in 32.7% of evaluable patients, underscoring robust response rates in this cohort.
  • With a 24-month progression-free survival at 88.4%, the combination of Ven-Obi proves beneficial in managing CLL.
  • Adverse events like hematologic toxicity often led to dose reductions, pointing to the need for careful patient monitoring.

Cite This Study

Zielonka et al. (2025) studied this question.

synapsesocial.com/papers/68c23f63b210217d647961f2https://doi.org/10.1080/10428194.2025.2535693
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL2025
  2. 2Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population2025
  3. 3First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry2025
  4. 4Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  5. 5Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia2025